At AHA 2024, the safety of GLP-1R agonists in heart failure and chronic kidney disease (CKD) patients was discussed.

New data from Barinthus Bio's HBV003 trial has demonstrated durable HBsAG loss in participants with chronic hepatitis B.

Gilead Sciences has reported two-and-a-half-year interim analysis outcomes from a Phase III study of Livdelzi (seladelpar) ...

The topline results found that the TenNor rifasutenizol trial showed better safety and tolerability than the current standard ...

The discussion at AHA emphasised that the FLOW trial established that semaglutide prevents major kidney outcomes and major ...

The ASI drug class potentially fills an unmet need in the CKD space. Credit: crystal light via Shutterstock. On 15 November ...

The failure of the Eyenovia CHAPERONE study has seen the company’s stock value drop drastically as it weighs up options and ...

GlobalData forecasts that the prostate cancer market is set to increase by 25% from $475.84 million in 2024 to $596.22 ...

Eli Lilly has reported comprehensive outcomes from the SURMOUNT-1 study of tirzepatide for treating pre-diabetic and obese ...

GSK has announced positive headline outcomes from a Phase III trial of Blenrep with bortezomib and dexamethasone for multiple ...

Microbion has reported positive topline results from its Phase II study of pravibismane, a topical treatment for DFI.

AC Immune’s Phase II trial showed an increase in anti-a-syn antibodies following treatment with the Parkinson’s disease ...